Skip to Main Content

Paper Details

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Prostate
9
2021
ATM, ATM mutations, BRCA1, BRCA1/2, BRCA2, DNA damage response genes, Men, PARPi, PSA50, Patients, abiraterone, docetaxel, enzalutamide, gATM, gATM mutations, gBRCA2, men, metastatic castration resistant prostate cancer, metastatic prostate cancer, patients, prostate cancer, prostate-specific antigen
Author NameAffiliation
Celestia S HiganoFred Hutchinson Cancer Research Center
Celestia S HiganoUniversity of Washington
Bruce MontgomeryUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Evan Y YuFred Hutchinson Cancer Research Center
Evan Y YuUniversity of Washington
Channing J PallerJohns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center
Oliver SartorTulane University School of Medicine
Emmanuel S AntonarakisJohns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center
Heather H ChengFred Hutchinson Cancer Research Center
Heather H ChengUniversity of Washington
  • 1 - 14

Datasets

Release 1.2